Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- BRD 2 3 4 bromo-domain RING 3 RNF anti-viral SARS-CoV-2 SARSCoV2 covid-19 covid19 coronavirus corona virus
- Product Overview:
Bromodomain-containing 2 (BRD2) is a transcriptional regulator that is a member of the bromodomain and extra-terminal (BET) family.{33144} It is ubiquitously expressed and localizes to the nucleus. BRD2 is composed of two N-terminal bromodomains (BD1 and BD2) that bind acetylated lysine on histones, serving to couple histone acetylation marks to the transcriptional regulation of target promoters, and an extra-terminal domain that mediates chromatin interactions.{33144,55056} BRD2 associates with transcription effector and regulator proteins, including RNA polymerase II, histone acetylases and deacetylases, and transcriptional co-activators and co-repressors to form a transcription complex that regulates the expression of genes involved in inflammation and cell proliferation.{33144,55055} BRD2 also binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein, a transmembrane protein involved in CoV virion assembly and pathogenesis of the related virus, SARS-CoV.{55024,53462,49521} siRNA knockdown of Brd2 reduces LPS-induced production of TNF and IL-6 in mouse bone marrow-derived macrophages (BMDMs).{24715} Genetic deletion of Brd2 in mice induces neural tube defects and is embryonic lethal.{33144} Brd2+/- mice have decreased numbers of GABAergic neurons and a reduced flurothyl-induced seizure threshold. SNPs in BRD2 have been found in individuals with juvenile myoclonic epilepsy. Cayman’s BRD2 bromodomains 1 and 2 (human, recombinant) protein can be used for Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.